Apply to trial NCT05870423

A few quick questions so the study team can decide if you might be a fit.

RecruitingPhase 1Drug trial

Improving Peptide Receptor Radionuclide Therapy With PARP Inhibitors

This is a phase 1 dose-escalation study to determine the maximum tolerated dose of the PARP inhibitor olaparib in combination with PRRT in patients with a well-differentiated advanced gastroenteropancreatic NET (GEP NET), progressive after PRRT. As secondary objectives, efficacy, pharmacokinetics and biomarker response will be investigated.

How this works

Answer a few questions
About 5 to 10 minutes. Skip-friendly where possible.
We connect you with the study team
When a site picks up your application, we introduce you to their team directly — with you on the thread.
The team reaches out to schedule screening
Usually within a few business days, via the contact you give.

EmailWe save your progress under this email and copy you when we connect you with the study team.

I agree that Hipa.ai may share my application — my name, contact details, and my answers, including health information — with the official study team for this trial so they can review my responses and contact me.

By continuing, you agree to our terms of service.

Improving Peptide Receptor Radionuclide Therapy With PARP Inhibitors

How this works

Answer a few questions

We connect you with the study team

The team reaches out to schedule screening